Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus HC 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus HC 4.
ALA-SCALP vs HC #4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
HC #4 is a complex homeopathic preparation with no well-defined molecular mechanism; it is believed to act via hormesis or placebo effects.
Topical application of a 5% solution to the scalp twice daily.
Hydrocortisone 100-300 mg IV bolus, followed by 100-200 mg IV every 6 hours for 24-48 hours; then taper as clinically indicated.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal elimination half-life: 12 hours (range 10–14 hours). Extends to 24 hours in severe renal impairment (CrCl <30 mL/min); dose adjustment recommended.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Renal excretion of unchanged drug: 95%; fecal/biliary: <5%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid